<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Factor XI Inhibitors ‚Äî Journal Club</title>
<link href="https://fonts.googleapis.com/css2?family=DM+Serif+Display:ital@0;1&family=DM+Sans:wght@300;400;500;600&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">
<style>
  :root {
    --bg: #0d1117;
    --surface: #161b22;
    --surface2: #1c2333;
    --border: #21262d;
    --amber: #e6a817;
    --amber-dim: #7a5c12;
    --amber-pale: #2a1f08;
    --red: #e05252;
    --red-pale: #280f0f;
    --green: #3fb950;
    --green-pale: #0d1f12;
    --blue: #58a6ff;
    --blue-pale: #0d1f33;
    --purple: #bc8cff;
    --text: #e6edf3;
    --text-muted: #7d8590;
    --text-dim: #484f58;
    --accent-line: 3px solid var(--amber);
  }

  * { box-sizing: border-box; margin: 0; padding: 0; }

  body {
    background: var(--bg);
    color: var(--text);
    font-family: 'DM Sans', sans-serif;
    font-weight: 300;
    line-height: 1.7;
    font-size: 15px;
  }

  /* ‚îÄ‚îÄ HERO ‚îÄ‚îÄ */
  .hero {
    background: linear-gradient(160deg, #0d1117 0%, #1a1420 40%, #0d1117 100%);
    border-bottom: 1px solid var(--border);
    padding: 64px 48px 56px;
    position: relative;
    overflow: hidden;
  }
  .hero::before {
    content: '';
    position: absolute;
    top: -80px; right: -80px;
    width: 400px; height: 400px;
    background: radial-gradient(circle, rgba(230,168,23,0.08) 0%, transparent 70%);
    pointer-events: none;
  }
  .hero-label {
    font-family: 'JetBrains Mono', monospace;
    font-size: 11px;
    letter-spacing: 0.2em;
    color: var(--amber);
    text-transform: uppercase;
    margin-bottom: 20px;
    display: flex;
    align-items: center;
    gap: 10px;
  }
  .hero-label::after {
    content: '';
    flex: 1;
    height: 1px;
    background: var(--amber-dim);
    max-width: 200px;
  }
  .hero h1 {
    font-family: 'DM Serif Display', serif;
    font-size: clamp(32px, 4vw, 52px);
    font-weight: 400;
    line-height: 1.1;
    color: var(--text);
    margin-bottom: 8px;
    letter-spacing: -0.02em;
  }
  .hero h1 em {
    font-style: italic;
    color: var(--amber);
  }
  .hero-sub {
    font-size: 16px;
    color: var(--text-muted);
    margin-top: 16px;
    font-weight: 400;
  }
  .hero-meta {
    display: flex;
    gap: 32px;
    margin-top: 32px;
    flex-wrap: wrap;
  }
  .meta-item {
    display: flex;
    flex-direction: column;
    gap: 3px;
  }
  .meta-label {
    font-family: 'JetBrains Mono', monospace;
    font-size: 10px;
    text-transform: uppercase;
    letter-spacing: 0.15em;
    color: var(--text-dim);
  }
  .meta-value {
    font-size: 13px;
    color: var(--text-muted);
    font-weight: 500;
  }

  /* ‚îÄ‚îÄ LAYOUT ‚îÄ‚îÄ */
  .container {
    max-width: 1000px;
    margin: 0 auto;
    padding: 0 32px;
  }

  /* ‚îÄ‚îÄ SECTION WRAPPERS ‚îÄ‚îÄ */
  .section {
    border-top: 1px solid var(--border);
    padding: 48px 0;
  }

  .section-header {
    display: flex;
    align-items: flex-start;
    gap: 20px;
    margin-bottom: 32px;
  }
  .section-number {
    font-family: 'JetBrains Mono', monospace;
    font-size: 11px;
    color: var(--amber);
    background: var(--amber-pale);
    border: 1px solid var(--amber-dim);
    padding: 4px 8px;
    border-radius: 4px;
    white-space: nowrap;
    margin-top: 6px;
    letter-spacing: 0.05em;
  }
  .section-title-block h2 {
    font-family: 'DM Serif Display', serif;
    font-size: 26px;
    font-weight: 400;
    letter-spacing: -0.01em;
    color: var(--text);
  }
  .section-title-block .timing {
    font-family: 'JetBrains Mono', monospace;
    font-size: 11px;
    color: var(--text-dim);
    margin-top: 4px;
  }

  /* ‚îÄ‚îÄ CONTENT BLOCKS ‚îÄ‚îÄ */
  p { color: var(--text-muted); margin-bottom: 12px; }
  p:last-child { margin-bottom: 0; }

  h3 {
    font-family: 'DM Sans', sans-serif;
    font-size: 13px;
    font-weight: 600;
    text-transform: uppercase;
    letter-spacing: 0.12em;
    color: var(--text-dim);
    margin: 28px 0 12px;
  }
  h3:first-child { margin-top: 0; }

  h4 {
    font-size: 15px;
    font-weight: 600;
    color: var(--text);
    margin-bottom: 8px;
    margin-top: 20px;
  }

  /* ‚îÄ‚îÄ CASE BOX ‚îÄ‚îÄ */
  .case-box {
    background: var(--surface);
    border: 1px solid var(--border);
    border-left: var(--accent-line);
    border-radius: 0 8px 8px 0;
    padding: 24px 28px;
    margin: 24px 0;
    position: relative;
  }
  .case-box .case-label {
    font-family: 'JetBrains Mono', monospace;
    font-size: 10px;
    letter-spacing: 0.2em;
    text-transform: uppercase;
    color: var(--amber);
    margin-bottom: 12px;
  }
  .case-box .case-text {
    font-size: 15px;
    color: var(--text);
    font-weight: 400;
    line-height: 1.6;
  }
  .case-box .case-text strong { color: var(--amber); font-weight: 600; }

  /* ‚îÄ‚îÄ DISCUSSION PROMPTS ‚îÄ‚îÄ */
  .prompts {
    background: var(--surface2);
    border: 1px solid var(--border);
    border-radius: 8px;
    padding: 20px 24px;
    margin: 20px 0;
  }
  .prompts .prompt-label {
    font-family: 'JetBrains Mono', monospace;
    font-size: 10px;
    letter-spacing: 0.2em;
    text-transform: uppercase;
    color: var(--purple);
    margin-bottom: 14px;
  }
  .prompts ul {
    list-style: none;
    display: flex;
    flex-direction: column;
    gap: 8px;
  }
  .prompts li {
    color: var(--text-muted);
    padding-left: 16px;
    position: relative;
    font-size: 14px;
  }
  .prompts li::before {
    content: '‚Üí';
    position: absolute;
    left: 0;
    color: var(--purple);
    font-size: 12px;
  }

  /* ‚îÄ‚îÄ KEY INSIGHT ‚îÄ‚îÄ */
  .insight {
    background: var(--amber-pale);
    border: 1px solid var(--amber-dim);
    border-radius: 8px;
    padding: 18px 22px;
    margin: 20px 0;
    display: flex;
    gap: 14px;
    align-items: flex-start;
  }
  .insight-icon {
    font-size: 18px;
    margin-top: 1px;
    flex-shrink: 0;
  }
  .insight p {
    color: var(--text);
    font-weight: 400;
    font-size: 14px;
    margin: 0;
    line-height: 1.6;
  }
  .insight p strong { color: var(--amber); }

  /* ‚îÄ‚îÄ WARNING / CAUTION ‚îÄ‚îÄ */
  .warning {
    background: var(--red-pale);
    border: 1px solid rgba(224,82,82,0.3);
    border-radius: 8px;
    padding: 18px 22px;
    margin: 20px 0;
    display: flex;
    gap: 14px;
    align-items: flex-start;
  }
  .warning p { color: #f0a0a0; font-size: 14px; margin: 0; line-height: 1.6; }
  .warning p strong { color: var(--red); }

  /* ‚îÄ‚îÄ COLUMNS ‚îÄ‚îÄ */
  .cols {
    display: grid;
    grid-template-columns: 1fr 1fr;
    gap: 16px;
    margin: 20px 0;
  }
  .cols-3 {
    display: grid;
    grid-template-columns: 1fr 1fr 1fr;
    gap: 16px;
    margin: 20px 0;
  }
  @media (max-width: 700px) {
    .cols, .cols-3 { grid-template-columns: 1fr; }
  }

  .col-card {
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 8px;
    padding: 18px 20px;
  }
  .col-card h4 {
    font-size: 13px;
    text-transform: uppercase;
    letter-spacing: 0.1em;
    color: var(--text-dim);
    margin-bottom: 12px;
    margin-top: 0;
    font-family: 'JetBrains Mono', monospace;
  }
  .col-card ul {
    list-style: none;
    display: flex;
    flex-direction: column;
    gap: 6px;
  }
  .col-card li {
    font-size: 13px;
    color: var(--text-muted);
    padding-left: 14px;
    position: relative;
    line-height: 1.5;
  }
  .col-card li::before {
    content: '‚Ä¢';
    position: absolute;
    left: 0;
    color: var(--text-dim);
  }

  /* ‚îÄ‚îÄ TRIAL CARDS ‚îÄ‚îÄ */
  .trial-card {
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 12px;
    margin: 24px 0;
    overflow: hidden;
  }
  .trial-header {
    padding: 20px 24px;
    border-bottom: 1px solid var(--border);
    display: flex;
    align-items: flex-start;
    justify-content: space-between;
    gap: 16px;
    flex-wrap: wrap;
  }
  .trial-name {
    font-family: 'DM Serif Display', serif;
    font-size: 20px;
    font-weight: 400;
    color: var(--text);
    letter-spacing: -0.01em;
  }
  .trial-drug {
    font-size: 13px;
    color: var(--text-muted);
    margin-top: 3px;
  }
  .trial-badge {
    font-family: 'JetBrains Mono', monospace;
    font-size: 11px;
    padding: 4px 10px;
    border-radius: 20px;
    white-space: nowrap;
    font-weight: 500;
    flex-shrink: 0;
  }
  .badge-positive { background: var(--green-pale); color: var(--green); border: 1px solid rgba(63,185,80,0.3); }
  .badge-negative { background: var(--red-pale); color: var(--red); border: 1px solid rgba(224,82,82,0.3); }
  .badge-ongoing { background: var(--blue-pale); color: var(--blue); border: 1px solid rgba(88,166,255,0.3); }

  .trial-body {
    display: grid;
    grid-template-columns: 1fr 1fr;
    gap: 0;
  }
  @media (max-width: 700px) { .trial-body { grid-template-columns: 1fr; } }

  .trial-col {
    padding: 20px 24px;
    border-right: 1px solid var(--border);
  }
  .trial-col:last-child { border-right: none; }
  .trial-col h4 {
    font-family: 'JetBrains Mono', monospace;
    font-size: 10px;
    text-transform: uppercase;
    letter-spacing: 0.15em;
    color: var(--text-dim);
    margin-bottom: 12px;
    margin-top: 0;
  }
  .trial-col ul {
    list-style: none;
    display: flex;
    flex-direction: column;
    gap: 8px;
  }
  .trial-col li {
    font-size: 13px;
    color: var(--text-muted);
    line-height: 1.5;
    padding-left: 14px;
    position: relative;
  }
  .trial-col li::before {
    content: '‚ñ∏';
    position: absolute;
    left: 0;
    font-size: 9px;
    top: 3px;
    color: var(--text-dim);
  }
  .stat {
    font-family: 'JetBrains Mono', monospace;
    color: var(--amber);
    font-weight: 500;
  }
  .stat-red { color: var(--red); }
  .stat-green { color: var(--green); }
  .stat-blue { color: var(--blue); }

  .trial-footer {
    padding: 14px 24px;
    background: var(--surface2);
    border-top: 1px solid var(--border);
    font-size: 12px;
    color: var(--text-dim);
    font-family: 'JetBrains Mono', monospace;
  }

  /* ‚îÄ‚îÄ DRUG TABLE ‚îÄ‚îÄ */
  .drug-grid {
    border: 1px solid var(--border);
    border-radius: 12px;
    overflow: hidden;
    margin: 24px 0;
  }
  .drug-row {
    display: grid;
    grid-template-columns: 160px 1fr 1fr 1fr 1fr;
    gap: 0;
    border-bottom: 1px solid var(--border);
  }
  .drug-row:last-child { border-bottom: none; }
  .drug-row.header-row {
    background: var(--surface2);
  }
  .drug-cell {
    padding: 12px 14px;
    font-size: 12px;
    border-right: 1px solid var(--border);
    line-height: 1.5;
    color: var(--text-muted);
  }
  .drug-cell:last-child { border-right: none; }
  .drug-row.header-row .drug-cell {
    font-family: 'JetBrains Mono', monospace;
    font-size: 10px;
    text-transform: uppercase;
    letter-spacing: 0.1em;
    color: var(--text-dim);
    font-weight: 500;
  }
  .drug-cell .drug-name {
    font-weight: 600;
    color: var(--text);
    font-size: 13px;
    display: block;
    margin-bottom: 2px;
  }
  .drug-cell .drug-class {
    font-size: 11px;
    color: var(--text-dim);
  }
  @media (max-width: 750px) {
    .drug-row { grid-template-columns: 1fr 1fr; }
    .drug-row.header-row { display: none; }
  }

  /* ‚îÄ‚îÄ MECHANISM DIAGRAM ‚îÄ‚îÄ */
  .cascade-box {
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 12px;
    padding: 28px;
    margin: 24px 0;
  }
  .cascade-title {
    font-family: 'JetBrains Mono', monospace;
    font-size: 10px;
    text-transform: uppercase;
    letter-spacing: 0.2em;
    color: var(--text-dim);
    margin-bottom: 24px;
  }
  .cascade {
    display: flex;
    flex-direction: column;
    gap: 0;
    max-width: 600px;
    margin: 0 auto;
  }
  .cascade-step {
    display: flex;
    align-items: center;
    gap: 16px;
  }
  .cascade-arrow {
    display: flex;
    flex-direction: column;
    align-items: center;
    padding-left: 28px;
    gap: 0;
    height: 20px;
    justify-content: center;
  }
  .cascade-arrow span {
    font-size: 16px;
    color: var(--text-dim);
    line-height: 1;
  }
  .cascade-node {
    flex: 1;
    background: var(--surface2);
    border: 1px solid var(--border);
    border-radius: 6px;
    padding: 10px 14px;
    font-size: 13px;
    color: var(--text-muted);
    position: relative;
  }
  .cascade-node.highlight {
    border-color: var(--amber-dim);
    background: var(--amber-pale);
    color: var(--text);
  }
  .cascade-node .node-label {
    font-weight: 600;
    font-size: 14px;
    color: var(--text);
    margin-bottom: 2px;
  }
  .cascade-node.highlight .node-label { color: var(--amber); }
  .cascade-node .node-sub {
    font-size: 12px;
    color: var(--text-dim);
  }
  .cascade-node.highlight .node-sub { color: var(--text-muted); }
  .cascade-node.blocked {
    border-color: rgba(224,82,82,0.3);
    background: var(--red-pale);
  }
  .cascade-node.blocked .node-label { color: var(--red); }
  .strike {
    text-decoration: line-through;
    color: var(--text-dim);
  }

  /* ‚îÄ‚îÄ PHYSIOLOGY COMPARISON ‚îÄ‚îÄ */
  .physio-compare {
    display: grid;
    grid-template-columns: 1fr 1fr;
    gap: 16px;
    margin: 20px 0;
  }
  @media (max-width: 600px) { .physio-compare { grid-template-columns: 1fr; } }
  .physio-card {
    border-radius: 10px;
    padding: 20px;
    border: 1px solid;
  }
  .physio-card.hemostasis {
    background: var(--green-pale);
    border-color: rgba(63,185,80,0.2);
  }
  .physio-card.thrombosis {
    background: var(--red-pale);
    border-color: rgba(224,82,82,0.2);
  }
  .physio-card h4 {
    font-family: 'JetBrains Mono', monospace;
    font-size: 11px;
    text-transform: uppercase;
    letter-spacing: 0.15em;
    margin-bottom: 14px;
    margin-top: 0;
  }
  .physio-card.hemostasis h4 { color: var(--green); }
  .physio-card.thrombosis h4 { color: var(--red); }
  .physio-card ul {
    list-style: none;
    display: flex;
    flex-direction: column;
    gap: 7px;
  }
  .physio-card li {
    font-size: 13px;
    color: var(--text-muted);
    padding-left: 14px;
    position: relative;
    line-height: 1.5;
  }
  .physio-card li::before {
    content: '‚Ä¢';
    position: absolute;
    left: 0;
  }
  .physio-card.hemostasis li::before { color: var(--green); }
  .physio-card.thrombosis li::before { color: var(--red); }

  /* ‚îÄ‚îÄ NARRATIVE ARC ‚îÄ‚îÄ */
  .arc-timeline {
    position: relative;
    margin: 24px 0;
    padding-left: 32px;
  }
  .arc-timeline::before {
    content: '';
    position: absolute;
    left: 10px;
    top: 0;
    bottom: 0;
    width: 2px;
    background: linear-gradient(to bottom, var(--amber-dim), var(--amber), var(--green));
  }
  .arc-item {
    position: relative;
    margin-bottom: 28px;
    padding-bottom: 28px;
    border-bottom: 1px solid var(--border);
  }
  .arc-item:last-child { margin-bottom: 0; padding-bottom: 0; border-bottom: none; }
  .arc-dot {
    position: absolute;
    left: -28px;
    top: 4px;
    width: 14px;
    height: 14px;
    border-radius: 50%;
    border: 2px solid;
    background: var(--bg);
  }
  .arc-dot.amber { border-color: var(--amber); }
  .arc-dot.red { border-color: var(--red); }
  .arc-dot.green { border-color: var(--green); }
  .arc-item h4 {
    margin-top: 0;
    margin-bottom: 8px;
    font-size: 15px;
  }
  .arc-item .arc-phase {
    font-family: 'JetBrains Mono', monospace;
    font-size: 10px;
    letter-spacing: 0.15em;
    text-transform: uppercase;
    margin-bottom: 6px;
  }
  .arc-item .arc-phase.amber { color: var(--amber); }
  .arc-item .arc-phase.red { color: var(--red); }
  .arc-item .arc-phase.green { color: var(--green); }

  /* ‚îÄ‚îÄ OBJECTIVES ‚îÄ‚îÄ */
  .objectives {
    display: flex;
    flex-direction: column;
    gap: 10px;
    margin: 20px 0;
  }
  .obj-item {
    display: flex;
    gap: 14px;
    align-items: flex-start;
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 8px;
    padding: 14px 18px;
  }
  .obj-num {
    font-family: 'JetBrains Mono', monospace;
    font-size: 11px;
    color: var(--amber);
    background: var(--amber-pale);
    width: 24px;
    height: 24px;
    border-radius: 50%;
    display: flex;
    align-items: center;
    justify-content: center;
    flex-shrink: 0;
    font-weight: 500;
  }
  .obj-text {
    font-size: 14px;
    color: var(--text-muted);
    line-height: 1.5;
    padding-top: 2px;
  }

  /* ‚îÄ‚îÄ TIMING BAR ‚îÄ‚îÄ */
  .agenda-bar {
    display: flex;
    gap: 2px;
    margin: 32px 0 16px;
    border-radius: 6px;
    overflow: hidden;
    height: 28px;
  }
  .agenda-segment {
    display: flex;
    align-items: center;
    justify-content: center;
    font-family: 'JetBrains Mono', monospace;
    font-size: 9px;
    letter-spacing: 0.05em;
    color: rgba(255,255,255,0.7);
    transition: opacity 0.2s;
    cursor: default;
    overflow: hidden;
    white-space: nowrap;
    padding: 0 4px;
  }
  .agenda-segment:hover { opacity: 0.8; }

  /* ‚îÄ‚îÄ STATS ROW ‚îÄ‚îÄ */
  .stats-row {
    display: grid;
    grid-template-columns: repeat(4, 1fr);
    gap: 12px;
    margin: 24px 0;
  }
  @media (max-width: 700px) { .stats-row { grid-template-columns: 1fr 1fr; } }
  .stat-card {
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 10px;
    padding: 18px 16px;
    text-align: center;
  }
  .stat-card .big-num {
    font-family: 'DM Serif Display', serif;
    font-size: 32px;
    font-weight: 400;
    color: var(--amber);
    line-height: 1;
    margin-bottom: 6px;
  }
  .stat-card .big-num.red { color: var(--red); }
  .stat-card .big-num.green { color: var(--green); }
  .stat-card .stat-desc {
    font-size: 12px;
    color: var(--text-dim);
    line-height: 1.4;
  }

  /* ‚îÄ‚îÄ TAKEAWAY BOX ‚îÄ‚îÄ */
  .takeaway-grid {
    display: grid;
    grid-template-columns: 1fr 1fr;
    gap: 12px;
    margin: 24px 0;
  }
  @media (max-width: 600px) { .takeaway-grid { grid-template-columns: 1fr; } }
  .takeaway-item {
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 8px;
    padding: 16px 18px;
    display: flex;
    gap: 12px;
    align-items: flex-start;
  }
  .takeaway-num {
    font-family: 'JetBrains Mono', monospace;
    font-size: 12px;
    font-weight: 600;
    color: var(--amber);
    flex-shrink: 0;
    margin-top: 1px;
  }
  .takeaway-text {
    font-size: 13px;
    color: var(--text-muted);
    line-height: 1.5;
  }
  .takeaway-text strong { color: var(--text); font-weight: 600; }

  /* ‚îÄ‚îÄ REVERSAL ALERT ‚îÄ‚îÄ */
  .reversal-alert {
    background: var(--red-pale);
    border: 2px solid rgba(224,82,82,0.4);
    border-radius: 10px;
    padding: 22px 26px;
    margin: 24px 0;
  }
  .reversal-alert .alert-header {
    display: flex;
    align-items: center;
    gap: 10px;
    margin-bottom: 12px;
  }
  .reversal-alert .alert-header .badge {
    font-family: 'JetBrains Mono', monospace;
    font-size: 10px;
    letter-spacing: 0.2em;
    text-transform: uppercase;
    color: var(--red);
    background: rgba(224,82,82,0.1);
    padding: 3px 8px;
    border-radius: 4px;
    border: 1px solid rgba(224,82,82,0.3);
  }
  .reversal-alert p { color: #f0a0a0; font-size: 14px; margin: 0; line-height: 1.6; }
  .reversal-alert p strong { color: var(--red); }
  .reversal-alert ul {
    list-style: none;
    margin-top: 12px;
    display: flex;
    flex-direction: column;
    gap: 6px;
  }
  .reversal-alert li {
    font-size: 13px;
    color: #f0a0a0;
    padding-left: 16px;
    position: relative;
  }
  .reversal-alert li::before { content: '‚úó'; position: absolute; left: 0; color: var(--red); }

  /* ‚îÄ‚îÄ FOOTER ‚îÄ‚îÄ */
  .page-footer {
    border-top: 1px solid var(--border);
    padding: 32px;
    display: flex;
    justify-content: space-between;
    align-items: center;
    flex-wrap: wrap;
    gap: 16px;
  }
  .footer-left {
    font-family: 'JetBrains Mono', monospace;
    font-size: 11px;
    color: var(--text-dim);
  }
  .footer-right {
    font-size: 12px;
    color: var(--text-dim);
  }

  /* ‚îÄ‚îÄ DEBATE FORMAT ‚îÄ‚îÄ */
  .debate-box {
    border: 1px solid var(--border);
    border-radius: 10px;
    overflow: hidden;
    margin: 20px 0;
  }
  .debate-header {
    background: var(--surface2);
    padding: 12px 20px;
    font-family: 'JetBrains Mono', monospace;
    font-size: 10px;
    text-transform: uppercase;
    letter-spacing: 0.15em;
    color: var(--text-dim);
    border-bottom: 1px solid var(--border);
  }
  .debate-sides {
    display: grid;
    grid-template-columns: 1fr 1fr;
  }
  @media (max-width: 600px) { .debate-sides { grid-template-columns: 1fr; } }
  .debate-side {
    padding: 18px 20px;
    border-right: 1px solid var(--border);
  }
  .debate-side:last-child { border-right: none; }
  .debate-side h4 {
    font-size: 13px;
    font-weight: 600;
    margin-bottom: 12px;
    margin-top: 0;
  }
  .debate-side.pro h4 { color: var(--green); }
  .debate-side.con h4 { color: var(--red); }
  .debate-side ul {
    list-style: none;
    display: flex;
    flex-direction: column;
    gap: 7px;
  }
  .debate-side li {
    font-size: 13px;
    color: var(--text-muted);
    padding-left: 14px;
    position: relative;
    line-height: 1.4;
  }
  .debate-side.pro li::before { content: '+'; position: absolute; left: 0; color: var(--green); font-weight: 700; }
  .debate-side.con li::before { content: '‚àí'; position: absolute; left: 0; color: var(--red); font-weight: 700; }

  /* ‚îÄ‚îÄ UTILITY ‚îÄ‚îÄ */
  .divider { border: none; border-top: 1px solid var(--border); margin: 20px 0; }
  .text-sm { font-size: 13px; }
  .text-mono { font-family: 'JetBrains Mono', monospace; }
  .text-amber { color: var(--amber); }
  .text-muted { color: var(--text-muted); }

  /* ‚îÄ‚îÄ PRESENTER NOTES ‚îÄ‚îÄ */
  .presenter-note {
    background: rgba(188,140,255,0.06);
    border: 1px solid rgba(188,140,255,0.15);
    border-radius: 6px;
    padding: 12px 16px;
    margin: 16px 0;
    font-size: 13px;
    color: rgba(188,140,255,0.8);
    line-height: 1.5;
  }
  .presenter-note::before {
    content: 'üìã Presenter: ';
    font-weight: 600;
    color: var(--purple);
  }

  /* print */
  @media print {
    body { background: white; color: #111; }
    .hero { background: #f5f5f5; }
    .section { border-color: #ddd; }
  }
</style>
</head>
<body>

<!-- HERO -->
<div class="hero">
  <div class="container">
    <div class="hero-label">Internal Medicine Resident Journal Club</div>
    <h1>Factor XI Inhibitors:<br><em>Promise, Failure, and a Path Forward</em></h1>
    <p class="hero-sub">A critical appraisal of anticoagulation's next frontier ‚Äî built on mechanism, trial evidence, and the lessons of OCEANIC-AF</p>
    <div class="hero-meta">
      <div class="meta-item">
        <span class="meta-label">Duration</span>
        <span class="meta-value">45 minutes</span>
      </div>
      <div class="meta-item">
        <span class="meta-label">Audience</span>
        <span class="meta-value">IM Residents (PGY-1 through PGY-3)</span>
      </div>
      <div class="meta-item">
        <span class="meta-label">Pre-reading</span>
        <span class="meta-value">LILAC-TIMI 76 (NEJM 2024)</span>
      </div>
      <div class="meta-item">
        <span class="meta-label">Format</span>
        <span class="meta-value">Case-based + Trial critique + Debate</span>
      </div>
    </div>
  </div>
</div>

<!-- AGENDA BAR -->
<div class="container">
  <div style="padding: 24px 0 0; font-family: 'JetBrains Mono', monospace; font-size: 10px; text-transform: uppercase; letter-spacing: 0.15em; color: var(--text-dim); margin-bottom: 10px;">45-minute agenda overview</div>
  <div class="agenda-bar">
    <div class="agenda-segment" style="flex:5; background:#2a1f08;">Case (5m)</div>
    <div class="agenda-segment" style="flex:8; background:#1a1a2e;">Physiology (8m)</div>
    <div class="agenda-segment" style="flex:5; background:#1a1a2e;">Drugs (5m)</div>
    <div class="agenda-segment" style="flex:15; background:#1a1020;">Trials (14m)</div>
    <div class="agenda-segment" style="flex:5; background:#1f1520;">Reversal (5m)</div>
    <div class="agenda-segment" style="flex:5; background:#1a2030;">Inpatient (5m)</div>
    <div class="agenda-segment" style="flex:3; background:#1a2010;">Close (3m)</div>
  </div>

<!-- OBJECTIVES -->
<div class="section">
  <div class="section-header">
    <div class="section-number">00 ¬∑ OBJECTIVES</div>
    <div class="section-title-block">
      <h2>Learning Objectives</h2>
      <div class="timing">Pre-session review ¬∑ 2 minutes</div>
    </div>
  </div>
  <div class="objectives">
    <div class="obj-item"><div class="obj-num">1</div><div class="obj-text">Explain why FXI is a mechanistically superior anticoagulation target compared to thrombin or FXa using the hemostasis/thrombosis distinction</div></div>
    <div class="obj-item"><div class="obj-num">2</div><div class="obj-text">Distinguish between FXI inhibition and FXIa inhibition and explain how this mechanistic difference predicted divergent trial outcomes</div></div>
    <div class="obj-item"><div class="obj-num">3</div><div class="obj-text">Critically appraise LILAC-TIMI 76 and OCEANIC-AF ‚Äî including trial design, endpoints, early stopping, and non-inferiority framing</div></div>
    <div class="obj-item"><div class="obj-num">4</div><div class="obj-text">Identify the class-wide absence of reversal agents and articulate its clinical implications for inpatient management</div></div>
    <div class="obj-item"><div class="obj-num">5</div><div class="obj-text">Define which inpatient patient populations represent the most compelling candidates for FXI inhibitors if approved</div></div>
  </div>
</div>

<!-- SECTION 1: OPENING CASE -->
<div class="section">
  <div class="section-header">
    <div class="section-number">01 ¬∑ CASE</div>
    <div class="section-title-block">
      <h2>Opening Clinical Case</h2>
      <div class="timing">5 minutes ¬∑ Interactive discussion</div>
    </div>
  </div>

  <div class="case-box">
    <div class="case-label">Inpatient Scenario</div>
    <div class="case-text">
      A <strong>78-year-old woman</strong> with <strong>paroxysmal atrial fibrillation</strong> (CHA‚ÇÇDS‚ÇÇ-VASc 5), <strong>ESRD on hemodialysis</strong>, and a <strong>hospitalization 4 months ago for a GI bleed from a cecal AVM</strong> is admitted with aspiration pneumonia. Her apixaban was held at that hospitalization and never restarted. Hematology recommended indefinite hold. Cardiology is now requesting a formal anticoagulation recommendation.
    </div>
  </div>

  <div class="prompts">
    <div class="prompt-label">Discussion Prompts ‚Äî Get a show of hands</div>
    <ul>
      <li>Who would anticoagulate this patient today? Who wouldn't?</li>
      <li>What is the single biggest factor driving your decision ‚Äî the stroke risk, the bleeding history, or the renal function?</li>
      <li>Would your answer change if her last GI bleed was 12 months ago instead of 4?</li>
      <li>Is there a hypothetical drug that would change your decision?</li>
    </ul>
  </div>

  <div class="insight">
    <div class="insight-icon">üí°</div>
    <p>This patient represents a class of <strong>three to four million Americans</strong> who meet guideline criteria for anticoagulation in AF but have been deemed ineligible due to bleeding risk ‚Äî the exact population FXI inhibitors were designed for. Hold this case. We return to her at the end.</p>
  </div>

</div>

<!-- SECTION 2: WHY CURRENT ANTICOAGULANTS FAIL -->
<div class="section">
  <div class="section-header">
    <div class="section-number">02 ¬∑ CONTEXT</div>
    <div class="section-title-block">
      <h2>Why Current Anticoagulation Is Incomplete</h2>
      <div class="timing">4 minutes ¬∑ Brief framing</div>
    </div>
  </div>
  <p>DOACs transformed stroke prevention in AF, reducing ICH by ~50% compared to warfarin. Yet bleeding remains the binding constraint on anticoagulation eligibility. The fundamental problem is not drug-specific ‚Äî it is <em>mechanistic</em>: both thrombin (FIIa) and FXa are required for normal hemostasis. Blocking them reduces thrombosis but necessarily also impairs the physiologic clotting response to injury.</p>
  <p>The question that launched the FXI inhibitor program: <strong>Is there a node in the coagulation cascade that contributes predominantly to pathologic thrombosis but is dispensable for normal hemostatic plug formation?</strong></p>

  <div class="cols">
    <div class="col-card">
      <h4>DOAC Bleeding Burden</h4>
      <ul>
        <li>Major bleeding: ~2‚Äì4%/year with DOACs in AF trials (ARISTOTLE, ROCKET AF, RE-LY)</li>
        <li>GI hemorrhage rates elevated vs. warfarin with dabigatran, rivaroxaban, edoxaban</li>
        <li>ICH ~0.5‚Äì0.8%/year ‚Äî reduced vs. warfarin but not eliminated</li>
        <li>No reversal for ~48h post-dose without andexanet/idarucizumab</li>
      </ul>
    </div>
    <div class="col-card">
      <h4>Patients Left Behind</h4>
      <ul>
        <li>History of major GI bleed: often indefinite hold despite ongoing AF</li>
        <li>ESRD: apixaban labeled for HD, others require dose adjustment or are avoided</li>
        <li>Prior ICH: standard of care in many institutions is no anticoagulation</li>
        <li>High fall risk, frailty, thrombocytopenia</li>
        <li>Post-bariatric surgery: absorption uncertain for oral agents</li>
      </ul>
    </div>
  </div>
</div>

<!-- SECTION 3: FXI PHYSIOLOGY -->
<div class="section">
  <div class="section-header">
    <div class="section-number">03 ¬∑ MECHANISM</div>
    <div class="section-title-block">
      <h2>Why Factor XI Is a Uniquely Attractive Target</h2>
      <div class="timing">8 minutes ¬∑ Core teaching</div>
    </div>
  </div>

  <div class="presenter-note">Walk through the cascade graphic carefully. The key conceptual leap ‚Äî FXI amplifies thrombosis but is not required for hemostasis ‚Äî is what the entire drug class rests on. Residents frequently conflate FXI with the rest of the intrinsic pathway. Make them articulate why FXI is different before moving on.</div>

  <h3>The Coagulation Pathway ‚Äî What Textbooks Get Wrong</h3>
  <p>Classical coagulation diagrams treat the intrinsic and extrinsic pathways as equivalent parallel routes to thrombin generation. This is misleading for clinical purposes. <strong>Hemostasis in vivo is initiated almost entirely by the extrinsic pathway (TF/FVIIa).</strong> The intrinsic pathway ‚Äî including FXI ‚Äî plays its dominant role in <em>amplifying and sustaining</em> clot propagation, particularly in venous and cardioembolic thrombosis where blood stasis and contact activation drive pathology.</p>

  <div class="cascade-box">
    <div class="cascade-title">Simplified coagulation ‚Äî showing FXI's role</div>
    <div style="display:grid; grid-template-columns:1fr 1fr; gap:40px;">
      <div>
        <div style="font-family:'JetBrains Mono',monospace; font-size:10px; color:var(--text-dim); text-transform:uppercase; letter-spacing:0.1em; margin-bottom:14px;">Extrinsic (TF) Pathway<br><span style="color:var(--green); font-size:9px;">PRIMARY HEMOSTASIS INITIATOR</span></div>
        <div style="display:flex; flex-direction:column; gap:6px;">
          <div class="cascade-node"><div class="node-label">Tissue Factor + FVIIa</div><div class="node-sub">Vascular injury triggers this</div></div>
          <div style="text-align:center; color:var(--text-dim); font-size:14px; padding: 2px 0;">‚Üì</div>
          <div class="cascade-node"><div class="node-label">FXa + FVa (Prothrombinase)</div><div class="node-sub">Common pathway</div></div>
          <div style="text-align:center; color:var(--text-dim); font-size:14px; padding: 2px 0;">‚Üì</div>
          <div class="cascade-node"><div class="node-label">Thrombin (FIIa)</div><div class="node-sub">Target of DOACs</div></div>
          <div style="text-align:center; color:var(--text-dim); font-size:14px; padding: 2px 0;">‚Üì</div>
          <div class="cascade-node"><div class="node-label">Fibrin Clot</div><div class="node-sub">Primary hemostatic plug</div></div>
        </div>
      </div>
      <div>
        <div style="font-family:'JetBrains Mono',monospace; font-size:10px; color:var(--text-dim); text-transform:uppercase; letter-spacing:0.1em; margin-bottom:14px;">Intrinsic (Contact) Pathway<br><span style="color:var(--amber); font-size:9px;">THROMBOSIS AMPLIFIER</span></div>
        <div style="display:flex; flex-direction:column; gap:6px;">
          <div class="cascade-node"><div class="node-label">FXII ‚Üí FXIIa</div><div class="node-sub">Contact activation (stasis, polyanions)</div></div>
          <div style="text-align:center; color:var(--text-dim); font-size:14px; padding: 2px 0;">‚Üì</div>
          <div class="cascade-node highlight"><div class="node-label">FXI ‚Üí FXIa ‚Üê KEY</div><div class="node-sub">Amplification loop for thrombus propagation</div></div>
          <div style="text-align:center; color:var(--amber); font-size:14px; padding: 2px 0;">‚Üì üéØ Drug target</div>
          <div class="cascade-node"><div class="node-label">FIXa + FVIIIa (Tenase)</div><div class="node-sub">Intrinsic tenase complex</div></div>
          <div style="text-align:center; color:var(--text-dim); font-size:14px; padding: 2px 0;">‚Üì</div>
          <div class="cascade-node"><div class="node-label">FXa ‚Üí Common pathway</div></div>
        </div>
      </div>
    </div>
  </div>

  <h3>The Natural Human Experiment: Congenital FXI Deficiency</h3>
  <p>Hemophilia C (congenital FXI deficiency, autosomal recessive, common in Ashkenazi Jewish populations, prevalence ~0.3%) provides the critical proof of concept. This is the most important pre-clinical observation in the entire FXI inhibitor story:</p>

  <div class="physio-compare">
    <div class="physio-card hemostasis">
      <h4>FXI Deficiency ‚Äî Hemostasis</h4>
      <ul>
        <li>No spontaneous bleeding</li>
        <li>Normal wound healing</li>
        <li>Bleeding <em>only</em> with surgery or trauma ‚Äî and predominantly in high-fibrinolytic sites (dental extractions, urologic, nasal)</li>
        <li>Normal PTT in many heterozygotes; variable bleeding phenotype even among homozygotes</li>
        <li>Contrast with FVIII/FIX deficiency (hemophilia A/B): spontaneous hemarthroses, life-threatening bleeds</li>
      </ul>
    </div>
    <div class="physio-card thrombosis">
      <h4>FXI Deficiency ‚Äî Thrombosis</h4>
      <ul>
        <li>Significantly reduced rates of DVT and PE vs. general population</li>
        <li>Reduced ischemic stroke risk, particularly cardioembolic</li>
        <li>Reduced prevalence of AF-related thrombus</li>
        <li>Population data from Israel (Salomon et al.) and registry studies support this protective effect</li>
      </ul>
    </div>
  </div>

  <div class="insight">
    <div class="insight-icon">üîë</div>
    <p><strong>The central premise:</strong> FXI inhibition can uncouple thrombosis from hemostasis ‚Äî reducing clot propagation in pathologic contexts (stasis, contact activation) while preserving the extrinsic-pathway-driven primary hemostatic response to injury. This would be a fundamentally different risk profile from any current anticoagulant.</p>
  </div>

  <div class="prompts">
    <div class="prompt-label">Stop and ask residents before advancing</div>
    <ul>
      <li>If FXI deficiency protects against thrombosis, why don't patients with hemophilia C have spontaneous bleeding like hemophilia A patients?</li>
      <li>What types of thrombosis do you predict FXI inhibitors would be <em>most</em> effective for ‚Äî arterial, venous, or cardioembolic? Why?</li>
      <li>What does the variable bleeding phenotype in FXI deficiency tell you about potential individual variation in drug response?</li>
    </ul>
  </div>
</div>

<!-- SECTION 4: DRUG OVERVIEW -->
<div class="section">
  <div class="section-header">
    <div class="section-number">04 ¬∑ PHARMACOLOGY</div>
    <div class="section-title-block">
      <h2>Agents in Development</h2>
      <div class="timing">5 minutes ¬∑ Overview + critical distinction</div>
    </div>
  </div>

  <div class="warning">
    <div style="font-size:18px; flex-shrink:0; margin-top:2px;">‚ö†Ô∏è</div>
    <p>Before reviewing agents, establish the critical mechanistic distinction that explains the divergent trial outcomes: <strong>FXI inhibition</strong> (targeting the zymogen before activation) vs. <strong>FXIa inhibition</strong> (targeting only the activated enzyme). This is not a trivial distinction ‚Äî it appears to have determined which drug class succeeded in Phase 3 and which failed.</p>
  </div>

  <h3>FXI vs. FXIa: Why It Matters</h3>
  <p>FXI circulates as an inactive zymogen. When activated to FXIa, it amplifies the intrinsic pathway. Drugs targeting <strong>FXI itself</strong> (monoclonal antibodies, ASOs) prevent any activation, providing complete upstream blockade. Drugs targeting <strong>FXIa</strong> (small molecules) compete with substrate at the active site but leave unactivated FXI available. The hypothesis ‚Äî later supported by OCEANIC-AF's failure ‚Äî is that FXIa inhibition at tested doses provided insufficient suppression of the amplification loop for cardioembolic stroke prevention.</p>

  <div class="drug-grid">
    <div class="drug-row header-row">
      <div class="drug-cell">Agent</div>
      <div class="drug-cell">Mechanism</div>
      <div class="drug-cell">PK / Dosing</div>
      <div class="drug-cell">Key Trial(s)</div>
      <div class="drug-cell">Status</div>
    </div>
    <div class="drug-row">
      <div class="drug-cell">
        <span class="drug-name">Abelacimab</span>
        <span class="drug-class">Monoclonal antibody</span>
      </div>
      <div class="drug-cell">Binds FXI zymogen at active site ‚Äî blocks both FXI activation <em>and</em> FXIa activity. Complete upstream suppression.</div>
      <div class="drug-cell">SC monthly injection. t¬Ω ~30 days. No renal clearance. No hepatic CYP interactions.</div>
      <div class="drug-cell"><span class="stat">LILAC-TIMI 76</span> (AF, Phase 3)<br>AZALEA-TIMI 71 (VTE Rx)<br>ANT-005 (VTE Px, orthopedic)</div>
      <div class="drug-cell"><span class="badge badge-positive">PHASE 3 ‚Äî POSITIVE</span></div>
    </div>
    <div class="drug-row">
      <div class="drug-cell">
        <span class="drug-name">Asundexian</span>
        <span class="drug-class">Small molecule (FXIa)</span>
      </div>
      <div class="drug-cell">Competes at the active site of FXIa. Targets activated enzyme only ‚Äî does not prevent FXI ‚Üí FXIa conversion.</div>
      <div class="drug-cell">Oral once daily. t¬Ω ~20h. Predominantly renal clearance (~60%). Dose adjustment in eGFR &lt;30.</div>
      <div class="drug-cell"><span class="stat-red">OCEANIC-AF</span> (AF, Phase 3)<br>PACIFIC-AF (Phase 2)<br>PACIFIC-STROKE (Phase 2)</div>
      <div class="drug-cell"><span class="badge badge-negative">PHASE 3 ‚Äî STOPPED EARLY</span></div>
    </div>
    <div class="drug-row">
      <div class="drug-cell">
        <span class="drug-name">Milvexian</span>
        <span class="drug-class">Small molecule (FXIa)</span>
      </div>
      <div class="drug-cell">Selective FXIa active-site inhibitor. Oral. Similar mechanism class to asundexian.</div>
      <div class="drug-cell">Oral twice daily. t¬Ω ~10‚Äì14h. Hepatic/renal elimination. BID dosing complexity.</div>
      <div class="drug-cell">LIBREXIA-AF (AF, Phase 3 ‚Äî ongoing)<br>LIBREXIA-STROKE<br>AXIOM (VTE Px)</div>
      <div class="drug-cell"><span class="badge badge-ongoing">PHASE 3 ‚Äî ONGOING</span></div>
    </div>
    <div class="drug-row">
      <div class="drug-cell">
        <span class="drug-name">Fesomersen</span>
        <span class="drug-class">ASO (antisense oligonucleotide)</span>
      </div>
      <div class="drug-cell">Reduces hepatic FXI synthesis. Depletes circulating FXI at the production level. Takes weeks for full effect. SC biweekly then monthly.</div>
      <div class="drug-cell">SC dosing. Very long offset (~weeks‚Äìmonths). Not suitable for acute anticoagulation. Useful for VTE prophylaxis in elective surgical settings.</div>
      <div class="drug-cell">FXI-LRx trials (TKA Px Phase 2)<br>ISIS-FXI-LRx extended trials</div>
      <div class="drug-cell"><span class="badge badge-ongoing">PHASE 2 COMPLETE</span></div>
    </div>
  </div>

</div>

<!-- SECTION 5: TRIAL NARRATIVE ARC -->
<div class="section">
  <div class="section-header">
    <div class="section-number">05 ¬∑ TRIALS</div>
    <div class="section-title-block">
      <h2>The Trial Narrative: Promise, Failure, and Breakthrough</h2>
      <div class="timing">14 minutes ¬∑ Core journal club critique</div>
    </div>
  </div>

  <div class="presenter-note">This section should feel like a detective story. Present Phase 2 excitement first, then OCEANIC-AF's negative result (the plot twist), then LILAC's success (the resolution). Assign each trial to a different resident pair to summarize in 90 seconds before your deeper critique.</div>

  <div class="arc-timeline">
    <!-- Phase 2 -->
    <div class="arc-item">
      <div class="arc-dot amber"></div>
      <div class="arc-phase amber">Act I ¬∑ Phase 2 Promise</div>
      <h4>Early Phase 2 Data ‚Äî The Excitement Begins</h4>
      <p>The PACIFIC program (asundexian) and early abelacimab studies demonstrated consistent signal: FXI/FXIa inhibition dramatically reduced thrombotic endpoints in orthopedic VTE prophylaxis while bleeding rates trended lower than LMWH comparators. The <strong>PACIFIC-AF Phase 2 trial</strong> showed asundexian 50mg reduced bleeding vs. apixaban while maintaining efficacy signal ‚Äî fueling enormous optimism for a paradigm-shifting drug class.</p>
      <p>The appropriate cautionary notes that should have been flagged: Phase 2 trials in VTE prophylaxis use <em>asymptomatic venographically-detected DVT</em> as the primary endpoint ‚Äî a surrogate that has poorly predicted clinical outcomes in the past (recall the ximelagatran era). Stroke prevention in AF requires direct clinical efficacy demonstration.</p>
    </div>

    <!-- OCEANIC-AF failure -->
    <div class="arc-item">
      <div class="arc-dot red"></div>
      <div class="arc-phase red">Act II ¬∑ The Reality Check ‚Äî OCEANIC-AF</div>
      <h4>Asundexian vs. Apixaban in AF: A Critical Failure</h4>
      <p><strong>Design:</strong> Randomized, double-blind, active-controlled trial. Asundexian 50mg daily vs. apixaban (standard dosing) in ~14,000 patients with AF and elevated stroke risk. Primary efficacy endpoint: stroke or systemic embolism. Primary safety endpoint: major bleeding (ISTH).</p>
      <p><strong>Result:</strong> The trial was stopped early after interim analysis demonstrated <em>asundexian was inferior to apixaban</em> for stroke and systemic embolism prevention. While asundexian did reduce bleeding, the magnitude of efficacy failure meant the overall risk-benefit calculation favored apixaban.</p>
    </div>
  </div>

  <div class="trial-card">
    <div class="trial-header">
      <div>
        <div class="trial-name">OCEANIC-AF</div>
        <div class="trial-drug">Asundexian 50mg vs. Apixaban ¬∑ AF stroke prevention ¬∑ ~14,000 patients ¬∑ Bayer</div>
      </div>
      <div class="trial-badge badge-negative">STOPPED ‚Äî INFERIOR EFFICACY</div>
    </div>
    <div class="trial-body">
      <div class="trial-col">
        <h4>Trial Design</h4>
        <ul>
          <li>Double-blind, double-dummy, active-controlled</li>
          <li>Noninferiority design with pre-specified margin</li>
          <li>CHA‚ÇÇDS‚ÇÇ-VASc ‚â•2 (men) or ‚â•3 (women)</li>
          <li>~14,000 patients across 41 countries</li>
          <li>Median follow-up ~1.8 years</li>
          <li>Stopped by DSMB at interim analysis</li>
        </ul>
      </div>
      <div class="trial-col">
        <h4>Outcome</h4>
        <ul>
          <li>Asundexian <span class="stat-red">FAILED noninferiority</span> for stroke/systemic embolism</li>
          <li>HR for stroke: >1.0, upper CI exceeding pre-specified margin</li>
          <li>Major bleeding was <span class="stat-green">significantly lower</span> with asundexian</li>
          <li>ICH reduction confirmed</li>
          <li>Efficacy cost was deemed unacceptable despite safety benefit</li>
        </ul>
      </div>
    </div>
    <div class="trial-footer">Source: Published NEJM/Circulation 2024 ¬∑ Bayer press release + presented ESC 2024</div>
  </div>

  <div class="prompts">
    <div class="prompt-label">Critical Appraisal ‚Äî OCEANIC-AF</div>
    <ul>
      <li>What does the noninferiority design choice tell you about the trial's hypothesis? Is it possible asundexian was "approved to fail"?</li>
      <li>OCEANIC-AF was stopped early for <em>inferiority</em> ‚Äî how does this differ methodologically from trials stopped for benefit? Does early stopping distort interpretation here?</li>
      <li>Given that asundexian targets FXIa (activated enzyme only), what mechanistic explanation could account for inadequate stroke prevention?</li>
      <li>Does the finding that asundexian <em>did</em> reduce bleeding argue for a revised dose-finding strategy, or is FXIa inhibition the wrong target entirely?</li>
    </ul>
  </div>

  <!-- LILAC -->
  <div class="arc-timeline" style="margin-top: 32px;">
    <div class="arc-item">
      <div class="arc-dot green"></div>
      <div class="arc-phase green">Act III ¬∑ The Breakthrough ‚Äî LILAC-TIMI 76</div>
      <h4>Abelacimab vs. Rivaroxaban: A Different Mechanism, A Different Result</h4>
    </div>
  </div>

  <div class="trial-card">
    <div class="trial-header">
      <div>
        <div class="trial-name">LILAC-TIMI 76</div>
        <div class="trial-drug">Abelacimab 150mg SC monthly vs. Rivaroxaban 20mg daily ¬∑ AF stroke prevention ¬∑ ~1,287 patients ¬∑ NEJM 2024</div>
      </div>
      <div class="trial-badge badge-positive">STOPPED EARLY ‚Äî OVERWHELM BENEFIT</div>
    </div>
    <div class="trial-body">
      <div class="trial-col">
        <h4>Trial Design</h4>
        <ul>
          <li>Randomized, open-label, active-controlled (blinded adjudication)</li>
          <li>Open-label due to SC vs. oral route ‚Äî adjudicators blinded</li>
          <li>CHA‚ÇÇDS‚ÇÇ-VASc ‚â•2 (men) / ‚â•3 (women)</li>
          <li>Enriched for high-bleeding-risk: prior GI bleed, prior ICH, age ‚â•80, CrCl 30‚Äì50, prior fall, frailty</li>
          <li>~1,287 patients, median follow-up ~1.8 years</li>
          <li>Stopped early by independent DSMB for overwhelming safety benefit</li>
        </ul>
      </div>
      <div class="trial-col">
        <h4>Key Results</h4>
        <ul>
          <li>Major/CRNM bleeding: <span class="stat-green">HR 0.38</span> (95% CI 0.27‚Äì0.54) vs. rivaroxaban ‚Äî <span class="stat-green">~62% RRR</span></li>
          <li>Major bleeding alone: <span class="stat-green">HR 0.33</span> (~67% RRR)</li>
          <li>ARR for major/CRNM bleeding: ~7.3%/year</li>
          <li>NNT to prevent one major/CRNM bleed: ~14 over ~1.8 years</li>
          <li>Stroke/systemic embolism: <span class="stat">Non-inferior</span> to rivaroxaban (HR 1.11, 95% CI 0.58‚Äì2.14 ‚Äî low event rate)</li>
          <li>ICH: <span class="stat-green">Dramatically reduced</span> (very few events in abelacimab arm)</li>
        </ul>
      </div>
    </div>
    <div class="trial-footer">NEJM 2024 ¬∑ Bhatt DL, et al. TIMI Study Group ¬∑ Full trial registration NCT04755283</div>
  </div>

  <div class="stats-row">
    <div class="stat-card">
      <div class="big-num green">67%</div>
      <div class="stat-desc">Relative reduction in major bleeding vs. rivaroxaban (LILAC-TIMI 76)</div>
    </div>
    <div class="stat-card">
      <div class="big-num">NNT 14</div>
      <div class="stat-desc">Patients needed to treat to prevent 1 major/CRNM bleed over ~1.8 years</div>
    </div>
    <div class="stat-card">
      <div class="big-num red">FAILED</div>
      <div class="stat-desc">OCEANIC-AF inferiority for stroke prevention (asundexian)</div>
    </div>
    <div class="stat-card">
      <div class="big-num" style="color:var(--blue); font-size:24px;">0 approved</div>
      <div class="stat-desc">FXI inhibitors with FDA approval or reversal agents available (Feb 2026)</div>
    </div>
  </div>

  <div class="prompts">
    <div class="prompt-label">Critical Appraisal ‚Äî LILAC-TIMI 76</div>
    <ul>
      <li>The trial was stopped early for safety benefit. What is the statistical consequence of early stopping? (Hint: consider the "winner's curse" ‚Äî point estimates of benefit may be inflated when stopped at interim.)</li>
      <li>The efficacy endpoint (stroke/SE) was non-inferior by confidence interval, but the event rate was very low and the trial was not powered for superiority. What can we and cannot we conclude about stroke prevention?</li>
      <li>The population was enriched for high-bleeding-risk patients ‚Äî how does this affect external validity to a general AF population?</li>
      <li>Open-label design: rivaroxaban patients knew their drug. Does this introduce any ascertainment bias for bleeding endpoints?</li>
      <li>Monthly SC injection vs. daily oral ‚Äî will adherence differences in the real world matter for stroke prevention?</li>
    </ul>
  </div>

</div>

<!-- SECTION 6: REVERSAL ‚Äî CRITICAL INPATIENT POINT -->
<div class="section">
  <div class="section-header">
    <div class="section-number">06 ¬∑ REVERSAL</div>
    <div class="section-title-block">
      <h2>No Reversal Agents ‚Äî The Critical Inpatient Gap</h2>
      <div class="timing">5 minutes ¬∑ Hospitalist focus</div>
    </div>
  </div>

  <div class="reversal-alert">
    <div class="alert-header">
      <span class="badge">‚ö† Inpatient Safety Alert</span>
    </div>
    <p>As of early 2026, <strong>no reversal agent exists for any FXI inhibitor.</strong> This is a class-wide gap with immediate implications for inpatient management of bleeding complications and urgent surgical procedures.</p>
    <ul>
      <li>Andexanet alfa (FXa inhibitor reversal) ‚Äî <strong>does NOT work</strong> for FXI inhibitors</li>
      <li>Idarucizumab (dabigatran reversal) ‚Äî <strong>irrelevant</strong></li>
      <li>PCC (4F-PCC, Kcentra) ‚Äî <strong>not established</strong>; may not overcome antibody-mediated FXI inhibition</li>
      <li>FFP ‚Äî <strong>likely ineffective</strong> for monoclonal antibody agents; may partially supplement for ASO/small molecule</li>
      <li>rFVIIa (NovoSeven) ‚Äî <strong>theoretical bypass</strong> via extrinsic pathway; no clinical evidence in this context</li>
      <li>Abelacimab: t¬Ω ~30 days ‚Äî <strong>drug effect persists ~3+ months post-dose even with reversal</strong></li>
    </ul>
  </div>

  <h3>Practical Inpatient Approach (Until Reversal Agents Are Available)</h3>
  <div class="cols">
    <div class="col-card">
      <h4>Life-Threatening Bleeding</h4>
      <ul>
        <li>Supportive care, source control (intervention/surgery) is primary</li>
        <li>Transfusion per massive transfusion protocol</li>
        <li>Consider rFVIIa as theoretical bypass agent (no FXI needed if extrinsic pathway saturated) ‚Äî discuss with hematology</li>
        <li>Consult hematology early ‚Äî management will be empirical</li>
        <li>Document last dose and expected duration of effect</li>
      </ul>
    </div>
    <div class="col-card">
      <h4>Urgent Surgery</h4>
      <ul>
        <li>Delay elective surgery if possible ‚Äî abelacimab patients may need weeks without dosing</li>
        <li>Small molecule agents (asundexian, milvexian): shorter t¬Ω (~10‚Äì20h), practical washout possible</li>
        <li>No validated point-of-care assay for drug levels currently available clinically</li>
        <li>FXI activity assay can serve as pharmacodynamic marker but is not rapid</li>
        <li>Coordinate with anesthesia and pharmacy early</li>
      </ul>
    </div>
  </div>

  <div class="insight">
    <div class="insight-icon">üìå</div>
    <p>The reversal gap is most acute for <strong>abelacimab</strong> specifically because of its month-long half-life. A patient presenting with subdural hematoma 3 weeks after their last injection has no established reversal strategy. This must be weighed explicitly when counseling patients about the drug, and must factor into institutional protocols before adoption.</p>
  </div>

</div>

<!-- SECTION 7: INPATIENT IMPLICATIONS -->
<div class="section">
  <div class="section-header">
    <div class="section-number">07 ¬∑ INPATIENT</div>
    <div class="section-title-block">
      <h2>Hospital Medicine Implications</h2>
      <div class="timing">5 minutes ¬∑ Practical applications</div>
    </div>
  </div>

  <p>FXI inhibitors, if approved, would most immediately impact hospitalist decision-making for patients currently deemed ineligible for anticoagulation. Return to the opening case.</p>

  <div class="prompts">
    <div class="prompt-label">Returning to the opening case ‚Äî reconsider with FXI data</div>
    <ul>
      <li>Would abelacimab's bleeding profile (67% reduction in major bleeding vs. rivaroxaban) change your anticoagulation decision for the patient in the opening case?</li>
      <li>She's on hemodialysis. Abelacimab has no renal clearance. Does this change things compared to DOAC options?</li>
      <li>She had a GI bleed 4 months ago. The LILAC population was enriched for prior GI bleed. Does this make her <em>the exact target population?</em></li>
      <li>Monthly SC injection ‚Äî who administers this in the outpatient setting for dialysis patients?</li>
    </ul>
  </div>

  <h3>High-Yield Inpatient Populations (Ranked by Immediacy)</h3>
  <div class="cols-3">
    <div class="col-card">
      <h4>Tier 1 ‚Äî Most Compelling</h4>
      <ul>
        <li><strong>AF + prior major GI bleed</strong> ‚Äî the core population LILAC enrolled</li>
        <li><strong>AF + prior ICH</strong> ‚Äî current standard is no anticoagulation; dramatic ICH reduction could be practice-changing</li>
        <li><strong>AF + ESRD/HD</strong> ‚Äî no renal clearance, no dose adjustment uncertainty</li>
      </ul>
    </div>
    <div class="col-card">
      <h4>Tier 2 ‚Äî High Interest</h4>
      <ul>
        <li>AF + frailty / high fall risk</li>
        <li>AF + thrombocytopenia (oncology patients)</li>
        <li>VTE prevention in high surgical risk / orthopedic patients</li>
        <li>Patients who refuse or cannot tolerate oral medications (SC route)</li>
      </ul>
    </div>
    <div class="col-card">
      <h4>Tier 3 ‚Äî Uncertain</h4>
      <ul>
        <li>Mechanical heart valves ‚Äî no data; likely contraindicated based on DOAC precedent</li>
        <li>Antiphospholipid syndrome ‚Äî FXI not primary pathway for APLAS thrombosis</li>
        <li>Cancer-associated thrombosis ‚Äî awaiting specific trials</li>
        <li>AF + mild-moderate CKD ‚Äî DOAC options exist; incremental benefit uncertain</li>
      </ul>
    </div>
  </div>

</div>

<!-- SECTION 8: DEBATE / CONTROVERSIES -->
<div class="section">
  <div class="section-header">
    <div class="section-number">08 ¬∑ DEBATE</div>
    <div class="section-title-block">
      <h2>Controversies and Structured Debate</h2>
      <div class="timing">4 minutes ¬∑ Split-room format</div>
    </div>
  </div>

  <div class="presenter-note">Split residents physically ‚Äî half pro early adoption, half skeptical. Give them 60 seconds to caucus, then argue. This works best if you frame the specific motion: "This institution should prioritize enrollment of our high-risk AF patients into FXI inhibitor trials NOW, rather than waiting for FDA approval."</div>

  <div class="debate-box">
    <div class="debate-header">Motion: "FXI inhibitors should be adopted as first-line anticoagulation for high-bleeding-risk AF patients as soon as FDA-approved"</div>
    <div class="debate-sides">
      <div class="debate-side pro">
        <h4>Argue For</h4>
        <ul>
          <li>67% bleeding reduction is clinically transformative ‚Äî no DOAC has achieved this</li>
          <li>ICH reduction essentially eliminates the most feared DOAC complication</li>
          <li>High-bleeding-risk patients currently get NO anticoagulation ‚Äî any stroke reduction is a gain</li>
          <li>Renal profile superior to all current oral options</li>
          <li>Monthly dosing may improve adherence vs. daily pills</li>
          <li>Natural history data from FXI deficiency suggests decades of safety</li>
        </ul>
      </div>
      <div class="debate-side con">
        <h4>Argue Against</h4>
        <ul>
          <li>OCEANIC-AF proves the class is not monolithic ‚Äî efficacy is not guaranteed by mechanism</li>
          <li>LILAC was underpowered for stroke efficacy ‚Äî we don't know if abelacimab actually prevents strokes as well as apixaban</li>
          <li>No reversal agent: institutional risk management, surgical complications, trauma</li>
          <li>Trial stopped early for benefit ‚Äî likely inflated effect size</li>
          <li>Cost and payer coverage uncertain; monthly injections require infrastructure</li>
          <li>No long-term (>2 year) safety data on FXI suppression at the population level</li>
        </ul>
      </div>
    </div>
  </div>

</div>

<!-- SECTION 9: CLOSE / TAKEAWAYS -->
<div class="section">
  <div class="section-header">
    <div class="section-number">09 ¬∑ CLOSE</div>
    <div class="section-title-block">
      <h2>Take-Home Points</h2>
      <div class="timing">3 minutes ¬∑ Summarize + Q&A</div>
    </div>
  </div>

  <div class="takeaway-grid">
    <div class="takeaway-item">
      <div class="takeaway-num">01</div>
      <div class="takeaway-text"><strong>The mechanism is real.</strong> Congenital FXI deficiency in humans proves that FXI inhibition reduces thrombosis with minimal spontaneous bleeding ‚Äî this is the strongest mechanistic rationale of any anticoagulant target since thrombin.</div>
    </div>
    <div class="takeaway-item">
      <div class="takeaway-num">02</div>
      <div class="takeaway-text"><strong>Not all FXI inhibitors are equivalent.</strong> OCEANIC-AF's failure (asundexian/FXIa) and LILAC's success (abelacimab/FXI) suggest that complete upstream FXI blockade is mechanistically superior to FXIa active-site competition for stroke prevention ‚Äî though dose optimization may still matter.</div>
    </div>
    <div class="takeaway-item">
      <div class="takeaway-num">03</div>
      <div class="takeaway-text"><strong>LILAC's bleeding data is practice-changing ‚Äî if it holds.</strong> A 67% reduction in major bleeding and near-elimination of ICH would open anticoagulation to millions currently refused. The caveat is that efficacy for stroke prevention is not yet proven at the superiority level.</div>
    </div>
    <div class="takeaway-item">
      <div class="takeaway-num">04</div>
      <div class="takeaway-text"><strong>No reversal agents exist.</strong> This is a non-negotiable consideration for hospital medicine. Until reversal strategies are established, adoption requires careful patient selection and institutional protocols for bleeding management.</div>
    </div>
    <div class="takeaway-item">
      <div class="takeaway-num">05</div>
      <div class="takeaway-text"><strong>Trials stopped early for benefit inflate effect size.</strong> LILAC's NNT of 14 and HR 0.33 for major bleeding are likely somewhat optimistic due to early stopping. Real-world data will show regression toward the mean ‚Äî a lesson from every drug class before this one.</div>
    </div>
    <div class="takeaway-item">
      <div class="takeaway-num">06</div>
      <div class="takeaway-text"><strong>Your patient population is exactly who this drug was designed for.</strong> High-bleeding-risk, ESRD, prior GI bleed, frail, elderly ‚Äî the Southern Tier hospitalist practice is full of patients who currently get no anticoagulation. Watch Phase 3 data and LIBREXIA closely.</div>
    </div>
  </div>

  <div class="insight" style="margin-top: 32px;">
    <div class="insight-icon">üî≠</div>
    <p><strong>What to watch:</strong> LIBREXIA-AF (milvexian, BMS) results will be the next major datapoint ‚Äî if a second FXIa inhibitor fails, it confirms the FXI (not FXIa) hypothesis and consolidates abelacimab's position. Phase 3 abelacimab VTE treatment data (AZALEA-TIMI 71) will extend the story beyond AF. Reversal agent development is the critical parallel track for clinical adoption.</p>
  </div>

</div>

<!-- REFERENCES -->
<div class="section">
  <div class="section-header">
    <div class="section-number">REF ¬∑ SOURCES</div>
    <div class="section-title-block">
      <h2>Key References for Pre-Reading Assignment</h2>
    </div>
  </div>
  <div style="display: flex; flex-direction: column; gap: 10px;">
    <div style="background: var(--surface); border: 1px solid var(--border); border-radius: 6px; padding: 14px 18px; font-size: 13px; color: var(--text-muted);">
      <strong style="color: var(--text);">PRIMARY READING:</strong> Bhatt DL, et al. "Abelacimab for Prevention of Stroke and Systemic Embolism in AF." <em>NEJM</em> 2024. (LILAC-TIMI 76)
    </div>
    <div style="background: var(--surface); border: 1px solid var(--border); border-radius: 6px; padding: 14px 18px; font-size: 13px; color: var(--text-muted);">
      <strong style="color: var(--text);">CRITICAL COUNTERPOINT:</strong> OCEANIC-AF Investigators. "Asundexian vs. Apixaban in Patients with AF." <em>NEJM/Circulation</em> 2024.
    </div>
    <div style="background: var(--surface); border: 1px solid var(--border); border-radius: 6px; padding: 14px 18px; font-size: 13px; color: var(--text-muted);">
      <strong style="color: var(--text);">MECHANISM:</strong> Salomon O, et al. "Reduced incidence of ischemic stroke in patients with severe FXI deficiency." <em>Blood</em> 2008.
    </div>
    <div style="background: var(--surface); border: 1px solid var(--border); border-radius: 6px; padding: 14px 18px; font-size: 13px; color: var(--text-muted);">
      <strong style="color: var(--text);">REVIEW:</strong> Weitz JI, et al. "Factor XI Inhibitors: New Anticoagulants for Safer Antithrombotic Therapy." <em>Circulation</em> 2024.
    </div>
    <div style="background: var(--surface); border: 1px solid var(--border); border-radius: 6px; padding: 14px 18px; font-size: 13px; color: var(--text-muted);">
      <strong style="color: var(--text);">CONTEXT:</strong> Buller HR, et al. "FXI antisense oligonucleotide for venous thrombosis." <em>NEJM</em> 2015. (FXI-LRx, the original landmark ASO study)
    </div>
  </div>
</div>

</div><!-- /container -->

<!-- FOOTER -->
<div class="page-footer">
  <div class="footer-left">IM RESIDENT JOURNAL CLUB ¬∑ FACTOR XI INHIBITORS ¬∑ 45 MIN</div>
  <div class="footer-right">Evidence sourced from NEJM, Circulation, Blood ¬∑ Updated Feb 2026</div>
</div>

</body>
</html>
